Principal Investigator
Byron Lam
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20250117
Clinical Trial Summary
A Double-Masked, Randomized, Placebo-Controlled, Paired-Eye Study to Evaluate the Efficacy, Safety and Tolerability of Sepofarsen in Subjects with Leber Congenital Amaurosis (LCA) due to the c.2991+1655A>G (p.Cys998X) Mutation in the CEP290 Gene
Phase
TBD
Funding Agency/Sponsor
Industry
Disease
Other